Company news
Veru Inc. news in 2023
Veru Inc.'s news releases, calls and decks from 2023, newest first.
Veru Announces Pricing of Public Offering of Common Stock
December 13, 2023
Veru Announces Proposed Public Offering of Common Stock
December 12, 2023
Veru Reports Muscle Data from 5 Clinical Studies of Enobosarm that Support the Advancement of Enobosarm in Combination with Weight-Loss GLP-1 Drugs, Ozempic®, Wegovy®, or Mounjaro®, to Optimize Weight Loss by Preventing Muscle Wasting and Further Incr...
October 3, 2023
Veru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin for Broader Indication: Hospitalized Adult Patients with Any Type of Viral Acute Respiratory Distress Syndrome (ARDS)
September 25, 2023
Veru Reports Fiscal 2023 Third Quarter Financial Results
August 9, 2023
Veru to Report Fiscal 2023 Third Quarter Financial Results on August 10, 2023
August 2, 2023
Veru Announces Appointment of Dr. Erik Swenson and Dr. Robert Schooley to its Infectious Disease Scientific Advisory Board
May 31, 2023
Veru Reports Fiscal 2023 Second Quarter Financial Results
May 10, 2023
Veru Reaches Agreement with FDA on Confirmatory Phase 3 Clinical Trial for Sabizabulin Treatment of Hospitalized COVID-19 Adult Patients at High Risk for ARDS
May 3, 2023
Veru Enters into Common Stock Purchase Agreement for Up to $100 Million with Lincoln Park Capital
May 2, 2023
Veru to Report Fiscal 2023 Second Quarter Financial Results on May 11, 2023
April 26, 2023
Veru Sells ENTADFI® Business for $20 Million Plus up to an Additional $80 Million from Sales Milestones
April 19, 2023
Veru Enters Into Supply Agreement with Afaxys to Expand Access to FC2 Female Condom® in U.S. Public Health Sector
April 18, 2023
Veru Announces Preclinical Study Results that Demonstrate Sabizabulin Inhibits Poxviruses
April 10, 2023
Veru Announces Preclinical Results from Expanded Sabizabulin Program into Influenza-Induced Severe Acute Respiratory Distress Syndrome and Provides Update on COVID-19 Program
April 3, 2023
Veru Provides FDA Update on Request for Emergency Use Authorization for Sabizabulin for Hospitalized COVID-19 Patients at High Risk for ARDS
March 1, 2023
Veru Reports Fiscal 2023 First Quarter Financial Results
February 8, 2023
Veru to Report Fiscal 2023 First Quarter Financial Results on February 9, 2023
January 25, 2023
Veru Announces Appointment of Dr. David D. Ho as Chairman of its Infectious Disease Scientific Advisory Board
January 9, 2023
Calls in 2023
Decks in 2023
- Investor Presentation (December 2023)
Investor deck · 19 slides · Dec 13, 2023